NL8204461A - Geneesmiddelen met een hoge mate van oplosbaarheid en werkwijze voor de bereiding hiervan. - Google Patents
Geneesmiddelen met een hoge mate van oplosbaarheid en werkwijze voor de bereiding hiervan. Download PDFInfo
- Publication number
- NL8204461A NL8204461A NL8204461A NL8204461A NL8204461A NL 8204461 A NL8204461 A NL 8204461A NL 8204461 A NL8204461 A NL 8204461A NL 8204461 A NL8204461 A NL 8204461A NL 8204461 A NL8204461 A NL 8204461A
- Authority
- NL
- Netherlands
- Prior art keywords
- solubility
- preparation
- high degree
- active substance
- drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 34
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 14
- 239000013543 active substance Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- -1 polyethylene Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 description 22
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 8
- 229960003313 hydroflumethiazide Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- BFCDFTHTSVTWOG-YLJYHZDGSA-N (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCN[C@H](C)[C@@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-YLJYHZDGSA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960000729 cyclandelate Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 229960003176 cyclothiazide Drugs 0.000 description 1
- BOCUKUHCLICSIY-QJWLJZLASA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1[C@H](C=C2)C[C@H]2C1 BOCUKUHCLICSIY-QJWLJZLASA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000374 eutectic mixture Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 1
- 229960000855 flavoxate Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- GWOFUCIGLDBNKM-UHFFFAOYSA-N glafenine Chemical compound OCC(O)COC(=O)C1=CC=CC=C1NC1=CC=NC2=CC(Cl)=CC=C12 GWOFUCIGLDBNKM-UHFFFAOYSA-N 0.000 description 1
- 229960001650 glafenine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 229960003967 suloctidil Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8206646A FR2525108B1 (fr) | 1982-04-19 | 1982-04-19 | Medicaments a haut degre de solubilite et procede pour leur obtention |
| FR8206646 | 1982-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8204461A true NL8204461A (nl) | 1983-11-16 |
Family
ID=9273120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8204461A NL8204461A (nl) | 1982-04-19 | 1982-11-18 | Geneesmiddelen met een hoge mate van oplosbaarheid en werkwijze voor de bereiding hiervan. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US4610875A (pm) |
| JP (1) | JPS58183615A (pm) |
| AR (1) | AR230183A1 (pm) |
| AT (1) | AT389813B (pm) |
| AU (1) | AU555579B2 (pm) |
| BE (1) | BE894942A (pm) |
| CA (1) | CA1225029A (pm) |
| CH (1) | CH655003A5 (pm) |
| DE (1) | DE3241097A1 (pm) |
| ES (1) | ES517444A0 (pm) |
| FR (1) | FR2525108B1 (pm) |
| GB (1) | GB2119784B (pm) |
| IE (1) | IE54084B1 (pm) |
| IT (1) | IT1153099B (pm) |
| LU (1) | LU84468A1 (pm) |
| NL (1) | NL8204461A (pm) |
| PT (1) | PT75867B (pm) |
| SE (1) | SE8206697L (pm) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
| JPS60139688A (ja) * | 1983-12-28 | 1985-07-24 | Tokyo Tanabe Co Ltd | 無定形ジヒドロピリジン粉末製剤 |
| EP0214092A1 (en) * | 1985-08-08 | 1987-03-11 | Ciba-Geigy Ag | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone |
| US4798725A (en) * | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
| US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
| US4832953A (en) * | 1987-08-13 | 1989-05-23 | Alza Corporation | Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix |
| WO1991007385A1 (en) * | 1989-11-18 | 1991-05-30 | Schering Agrochemicals Limited | Preparation of propenoic acid derivatives |
| IT1242642B (it) * | 1990-04-17 | 1994-05-16 | Alfa Wassermann Spa | Formulazioni iniettabili contenenti naproxen sale sodico. |
| JPH0648937A (ja) * | 1992-04-07 | 1994-02-22 | Seitai Kagaku Kenkyusho:Kk | 経口投与に適する薬剤およびその製造方法 |
| US5512300A (en) * | 1992-09-15 | 1996-04-30 | Warner-Lambert Company | Prevention of ibuprofen from forming low melting eutectics with other therapeutic agents in solid dosage forms |
| FR2722984B1 (fr) * | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
| US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| US5686133A (en) * | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
| WO1997034601A1 (fr) * | 1996-03-18 | 1997-09-25 | Eisai Co., Ltd. | Compositions medicamenteuses a solubilite amelioree |
| US6066339A (en) * | 1997-10-17 | 2000-05-23 | Elan Corporation, Plc | Oral morphine multiparticulate formulation |
| US6086915A (en) * | 1998-04-01 | 2000-07-11 | Bioresponse L.L.C. | Compositions and methods of adjusting steroid hormone metabolism through phytochemicals |
| PL193673B1 (pl) * | 1998-07-20 | 2007-03-30 | Smithkline Beecham Corp | Bezpostaciowa sól amonowa eprosartanu,jej granulat i biologicznie ulepszony preparat oraz sposoby ich wytwarzania i zastosowanie |
| WO2000020033A1 (fr) * | 1998-10-05 | 2000-04-13 | Eisai Co., Ltd. | Comprimes se delitant immediatement dans la cavite buccale |
| CA2359945C (en) * | 1999-11-12 | 2011-04-26 | Abbott Laboratories | Inhibitors of crystallization in a solid dispersion |
| US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
| NZ513964A (en) * | 1999-12-08 | 2004-01-30 | Pharmacia Corp | Solid-state form of celecoxib having enhanced bioavailability |
| WO2001047495A1 (en) | 1999-12-23 | 2001-07-05 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
| IL134701A0 (en) * | 2000-02-23 | 2001-04-30 | J P M E D Ltd | Homogeneous solid matrix containing vegetable proteins |
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| JP4875277B2 (ja) | 2000-06-16 | 2012-02-15 | 田辺三菱製薬株式会社 | 放出ｐＨ域及び／又は速度制御組成物 |
| BR0114896A (pt) * | 2000-10-24 | 2003-08-12 | Ajinomoto Kk | Preparação contendo nateglinida, e, método para produzir a mesma |
| EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| CA2448825C (en) * | 2001-06-22 | 2009-08-11 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drug |
| JP2004534811A (ja) * | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | ポリマーと薬剤の集合体を含む医薬組成物 |
| SI21223A (sl) * | 2002-06-19 | 2003-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| US20050152932A1 (en) * | 2003-06-12 | 2005-07-14 | Valery Normand | Non-crystalline perfume or flavor delivery system |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
| EP1827429A4 (en) * | 2004-12-20 | 2009-08-05 | Reddys Lab Ltd Dr | PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS BENZIMIDAZOLE COMPOUNDS |
| PL1868581T3 (pl) * | 2005-04-11 | 2012-08-31 | Abbvie Inc | Kompozycje farmaceutyczne słabo rozpuszczalnych leków o polepszonych profilach rozpuszczania |
| WO2006119779A2 (en) * | 2005-05-10 | 2006-11-16 | Lifecycle Pharma A/S | A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution |
| CA2640165A1 (en) * | 2006-01-27 | 2007-08-02 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin | A method of producing porous microparticles |
| PT103743B (pt) * | 2007-05-16 | 2013-01-15 | Hovione Farmaciencia S A | Processo para preparar derivados de 21-disódio fosfato de pregnanos. |
| NZ592549A (en) * | 2008-11-04 | 2012-09-28 | Cipla Ltd | A compex of tiotropium bromide and polyvinylpyrrolidone having a low degree of crystallinity |
| SG191316A1 (en) * | 2010-12-23 | 2013-07-31 | Abbott Gmbh & Co Kg | Solid retard formulations based on solid dispersions |
| WO2012164575A2 (en) | 2011-05-27 | 2012-12-06 | Hetero Research Foundation | Amorphous ritonavir co-precipitated |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151273A (en) * | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
| JPS5163925A (ja) * | 1974-11-30 | 1976-06-02 | Kyowa Hakko Kogyo Kk | Muteikeikuroramufuenikooruno seizoho |
| JPS51118816A (en) * | 1975-04-08 | 1976-10-19 | Meiji Seika Kaisha Ltd | A process for stabilizing non-crystalloidal solid |
| US4127647A (en) * | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
| DE2634004B2 (de) * | 1976-07-29 | 1978-08-10 | Bernhard Dr. 8000 Muenchen Lippold | Verfahren zur Beschleunigung der Auflösung und Verbesserung der Löslichkeit von schlechtlöslichen zur peroralen Verabreichung bestimmten Arzneistoffen |
| GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
| EP0001247A1 (en) * | 1977-09-14 | 1979-04-04 | Kanebo, Ltd. | Pharmaceutical preparation containing nifedipine and a method for producing the same. |
| US4128632A (en) * | 1978-02-13 | 1978-12-05 | Merck & Co., Inc. | Solubilization of Rafoxanide |
| US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
| JPS55139319A (en) * | 1979-04-13 | 1980-10-31 | Furointo Sangyo Kk | Activation of drug soluble in alkali and acid |
| JPS6024768B2 (ja) * | 1979-06-16 | 1985-06-14 | フロイント産業株式会社 | 活性化薬剤の製法 |
| JPS587609B2 (ja) * | 1979-06-17 | 1983-02-10 | フロイント産業株式会社 | 粉体薬剤のコ−テング法 |
| DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| JPS5948810B2 (ja) * | 1980-03-22 | 1984-11-29 | 山之内製薬株式会社 | ニカルジピン持続性製剤用組成物 |
| JPS5646837A (en) * | 1979-09-27 | 1981-04-28 | Kowa Yakuhin Kogyo Kk | Preparation of ibuprofen clathrate compound |
| JPS5655370A (en) * | 1979-10-13 | 1981-05-15 | Kyorin Pharmaceut Co Ltd | Amorphous nicomol |
| US4327080A (en) * | 1981-07-13 | 1982-04-27 | E. R. Squibb & Sons, Inc. | Novel Bendroflumethiazide formulations and method |
| FR2525108B1 (fr) * | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
| DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
-
1982
- 1982-04-19 FR FR8206646A patent/FR2525108B1/fr not_active Expired
- 1982-11-01 IE IE2610/82A patent/IE54084B1/en not_active IP Right Cessation
- 1982-11-04 GB GB08231580A patent/GB2119784B/en not_active Expired
- 1982-11-05 CA CA000415001A patent/CA1225029A/en not_active Expired
- 1982-11-06 DE DE19823241097 patent/DE3241097A1/de active Granted
- 1982-11-08 BE BE1/10635A patent/BE894942A/fr unknown
- 1982-11-11 AR AR291268A patent/AR230183A1/es active
- 1982-11-12 AU AU90431/82A patent/AU555579B2/en not_active Expired
- 1982-11-12 LU LU84468A patent/LU84468A1/fr unknown
- 1982-11-17 PT PT75867A patent/PT75867B/pt not_active IP Right Cessation
- 1982-11-17 ES ES517444A patent/ES517444A0/es active Granted
- 1982-11-18 NL NL8204461A patent/NL8204461A/nl active Search and Examination
- 1982-11-19 JP JP57204422A patent/JPS58183615A/ja active Granted
- 1982-11-23 IT IT24368/82A patent/IT1153099B/it active
- 1982-11-24 SE SE8206697A patent/SE8206697L/xx not_active Application Discontinuation
- 1982-11-24 AT AT0427282A patent/AT389813B/de not_active IP Right Cessation
- 1982-12-17 CH CH7389/82A patent/CH655003A5/fr not_active IP Right Cessation
-
1984
- 1984-08-31 US US06/646,485 patent/US4610875A/en not_active Expired - Lifetime
-
1986
- 1986-05-19 US US06/864,827 patent/US4769236A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AT389813B (de) | 1990-02-12 |
| FR2525108A1 (fr) | 1983-10-21 |
| ES8505249A1 (es) | 1985-05-16 |
| DE3241097C2 (pm) | 1989-04-13 |
| IE54084B1 (en) | 1989-06-07 |
| AR230183A1 (es) | 1984-03-01 |
| JPH0341444B2 (pm) | 1991-06-24 |
| IE822610L (en) | 1983-10-19 |
| SE8206697L (sv) | 1983-10-20 |
| AU9043182A (en) | 1983-10-27 |
| AU555579B2 (en) | 1986-10-02 |
| IT1153099B (it) | 1987-01-14 |
| DE3241097A1 (de) | 1983-10-20 |
| FR2525108B1 (fr) | 1989-05-12 |
| BE894942A (fr) | 1983-05-09 |
| ATA427282A (de) | 1989-07-15 |
| US4769236A (en) | 1988-09-06 |
| JPS58183615A (ja) | 1983-10-26 |
| LU84468A1 (fr) | 1983-06-13 |
| GB2119784B (en) | 1986-04-03 |
| CH655003A5 (fr) | 1986-03-27 |
| ES517444A0 (es) | 1985-05-16 |
| PT75867A (fr) | 1982-12-01 |
| IT8224368A0 (it) | 1982-11-23 |
| SE8206697D0 (sv) | 1982-11-24 |
| PT75867B (fr) | 1986-01-21 |
| US4610875A (en) | 1986-09-09 |
| GB2119784A (en) | 1983-11-23 |
| IT8224368A1 (it) | 1984-05-23 |
| CA1225029A (en) | 1987-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8204461A (nl) | Geneesmiddelen met een hoge mate van oplosbaarheid en werkwijze voor de bereiding hiervan. | |
| CA1281652C (en) | Readily absorbable pharmaceutical composition | |
| US5082863A (en) | Pharmaceutical composition of florfenicol | |
| JP3833248B2 (ja) | 簡単な組成及び高い生物有効性を有する経口投与のためのシクロスポリンの新規処方物及びその製造法 | |
| HK62889A (en) | Sucralfate suspension | |
| JPS6191117A (ja) | その場でのミセル形成によつて水溶性に乏しい薬剤の水溶解速度及び溶解度を増加するための新規な無水系 | |
| JPH0774162B2 (ja) | 水銀含有防腐剤を安定化した眼炎治療薬 | |
| HU197208B (en) | Process for production of medical compositions containing derivatives of oxicame | |
| NO960232L (no) | Fremgangsmåte for belegging av dråper eller nanopartikler | |
| US4900775A (en) | Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone | |
| EP0259982B1 (en) | Solid iodophor composition | |
| EP0196813A1 (en) | A process for the preparation of a free flowing, homogeneous, iodophor containing wound powder | |
| KR910003557B1 (ko) | 액체 서방성 약물 제형의 제조방법 | |
| JP2000281561A (ja) | 新規溶媒法固体分散体製剤 | |
| US4973553A (en) | Salt or organogermanium compound and medicine containing the same | |
| EP0088958B1 (en) | Stabilization of azulene derivatives | |
| IE47833B1 (en) | Process for solubilizing an insoluble drug and an aqueous solution prepared by this process | |
| HK1052873B (zh) | 可滴加的眼用两相水凝胶 | |
| Aleti et al. | Solubility and dissolution enhancement of cefixime using natural polymer by solid dispersion technique | |
| NL193441C (nl) | Farmaceutisch preparaat voor veterinair gebruik. | |
| US4452780A (en) | Coacervated iodine | |
| JPH02108604A (ja) | 水溶性農薬粒剤組成物 | |
| JPS61178914A (ja) | ヒト及び動物の耳への局所投与用不溶性薬剤 | |
| Rasheed et al. | Pharmaceutical Aids-a Review Study | |
| KR940006591A (ko) | 비루스성 감염치료 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BN | A decision not to publish the application has become irrevocable |